Thomas Bartl

@thomasbartlMD

Gynecogic Oncologist・Junior Faculty @MedUni_Wien ・Editorial Fellow @IJGConline

Vienna, Austria Joined January 2025

61 Following 43 Followers 10 Posts

Latest posts 4

Thomas Bartl @thomasbartlMD Mar 31, 2025

The low incidence of mucinous ovarian cancer continues to hinder both clinical and translational research. Prognosis remains unchanged for decades—with no Phase III trials in sight. It's time to shift the paradigm and drive progress!

IJGC Verified account @IJGConline Mar 29, 2025

#2025SpecialIssue Controversies in the management of mucinous #ovariantumors

🔎 bit.ly/42lkqK5

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @thomasbartlMD @kfischermd @claritasantia @stephjeangill @MMontesinos_Alb @braunchristian1 @mattmarchettiMD @yates_elisemann @jhgelissen

View quoted post on X

Thomas Bartl @thomasbartlMD Mar 19, 2025

Visiting Eurogin 2025 with Elmar Joura, who has been at the forefront of HPV research for 25 years @EUROGINHPV @ESGO_society @MedUni_Wien #hpv #hpvvaccination

Thomas Bartl @thomasbartlMD Feb 22, 2025

👟 ESGO Cancer Awareness Run: Check! Thank you all for your effort raising awareness for Gynecologic Cancers!
#esgo2025

Thomas Bartl @thomasbartlMD Feb 11, 2025

🚩Every third physician treating gynecologic cancer patients lacks confidence in managing checkpoint inhibitor side effects, underscoring the need for more specialized training and stronger interdisciplinary collaboration. #gynonc #oncoalert @AgoAustria
doi.org/10.1186/s12885…

link.springer.com The implementation and side effect management of immune checkpoint inhibitors in gynecologic... BMC Cancer - The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events...